Understanding how mitochondrial networks affect treatment response in advanced lung cancer
Official title: Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
Funded at University of California Los Angeles · NIH-11132193 · Data updated 2026-11-12
This study is looking at how the tiny energy factories in your cells, called mitochondria, might affect how well patients with advanced lung cancer respond to new targeted treatments, helping to find out why some people do better than others and paving the way for more personalized care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | March 12, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $531,379 |
| NIH project number | 1R01CA292866-01A1 |
| Project ID | NIH-11132193 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced or metastatic non-small cell lung cancer who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage lung cancer or those who have not yet undergone standard therapies may not benefit from this research.
What this research studies
This research investigates the role of mitochondrial networks in determining how well patients with advanced non-small cell lung cancer (NSCLC) respond to new antibody drug conjugates (ADCs). The study focuses on three specific ADCs that have shown promise after standard therapies have failed. By examining the biological mechanisms behind these treatments, the research aims to identify why some patients benefit while others do not. This could lead to more personalized treatment strategies for patients with advanced lung cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with advanced lung cancer, potentially increasing their chances of response to therapy.
How similar studies have gone: Other research has shown promising results with similar approaches in understanding treatment responses in cancer, indicating that this area of investigation is both relevant and potentially impactful.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Lisberg, Aaron Elliott — University of California Los Angeles
- Study coordinator: Lisberg, Aaron Elliott
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.